Chief Commercial Officer (CCO)

Veracyte initiated with neutral view at Canaccord, here's why

Freedom Capital Markets Initiates Coverage of Veracyte With Buy Rating and $45 Price Target

Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte Insider Sold Shares Worth $753,204, According to a Recent SEC Filing

Senior Manager, Risk Management

Veracyte is a global genomic diagnostics company that improves patient care by providing answers to clinical questions. The Sr. Manager, Risk Management will lead the company’s Third-Party Risk Management program, focusing on evaluating and mitigating risks associated with security, AI systems, and data privacy while ensuring compliance with regulatory requirements.

Vice President, Employment Law & Global HR

Sr Director, Total Rewards

Director of Compliance

Sr. Manager, Reimbursement Operations

Sign up with Google

Sign in with Google